Breaking News, Financial News

Financial Report: Roche 1H11

Group sales were stable in local currencies, up 2%.

Roche 1H11*

YTD Revenues: 21.7 billion (-12%)

YTD Earnings: 5.3 billion (-5%)

Comments: Group sales, excluding Tamiflu, were up 2% in local currencies to 21.4 billion. Pharmaceutical sales were down 11% to 16.8 billion (-1% in LC). The decrease in Avastin and Tamiflu sales, generic competition for CellCept, and competition for the NeoRecormon/Epogin franchise, was partially offset by continued growth of Herceptin, MabThera/Rituxan, Xeloda and Tarceva, Lucentis and Actemra/RoActemra. R&D costs were down 11% to 3.9 billion. Diagnostics Division sales fell 8% to 4.9 billion (+5% LC)

*All numbers reported in CHF

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters